ProActiN™ (Proteomic Activity Networks) is a specialized tool for clinical biomarker discovery that uses Snapshot Proteomics™ to provide information about changes to the proteome of dosed individuals. Specifically, ProActiN™ compares the differences in post-translational modification between related samples, such as a treated group vs. a control group, or responders vs. non-responders, to discover molecular signatures that can be prospectively used to identify one of the sample cohorts.
The result is the novel discovery of companion diagnostics (CDx), molecular diagnostics (MDx), and surrogate biomarkers for a wide range of therapeutic areas and drug treatments. Because ProActiN™ is measuring the pharmacodynamic changes to actual proteins, the results are both more accurate and reproducible than other leading biomarker techniques.
The ideal sample candidates for ProActin™ are from human clinical trials involving pharmaceutical compounds. To get started with ProActin™, please contact us to discuss your planned or ongoing clinical trial or biomarker discovery needs.
ProActiN™ reveals protein biomarkers for translational and clinical purposes including:
- Companion biomarker discovery (CDx)
- Diagnostic biomarker discovery (Dx)
- Surrogate biomarker discovery